Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 IL-24 armored CAR19-T cells show enhanced antitumor activity and persistence.

Literature DB >> 33441538

IL-24 armored CAR19-T cells show enhanced antitumor activity and persistence.

Qian Hu¹, Yuxuan Zhang¹, Peiyun Wang¹, Miaojin Zhou¹, Zhiqing Hu¹, Cong Liu¹, Mujun Liu¹, Lingqian Wu¹, Xionghao Liu^2,3, Desheng Liang^4,5.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2021 PMID： 33441538 PMCID： PMC7806903 DOI： 10.1038/s41392-020-00380-8

Source DB: PubMed Journal: Signal Transduct Target Ther ISSN： 2059-3635

× No keyword cloud information.

5 in total

Review 1. Targeted Nanoparticle Drug Delivery System for the Enhancement of Cancer Immunotherapy.

Authors: Haoran Zhang; Yanqi Wu; Yue Hu; Xiaofeng Li; Minyi Zhao; Zhiyue Lv
Journal: J Biomed Nanotechnol Date: 2019-09-01 Impact factor: 4.099

Review 2. Advances in targeted therapy for malignant lymphoma.

Authors: Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal: Signal Transduct Target Ther Date: 2020-03-06

3. Low expression of Mda-7/IL-24 and high expression of C-myb in tumour tissues are predictors of poor prognosis for Burkitt lymphoma patients.

Authors: Ming Ma; Riyang Zhao; Xingxiao Yang; Lianmei Zhao; Lihua Liu; Cong Zhang; Xuexiao Wang; Baoen Shan
Journal: Hematology Date: 2018-02-08 Impact factor: 2.269

4. A safe and potent anti-CD19 CAR T cell therapy.

Authors: Zhitao Ying; Xue F Huang; Xiaoyu Xiang; Yanling Liu; Xi Kang; Yuqin Song; Xiaokai Guo; Hanzhi Liu; Ning Ding; Tingting Zhang; Panpan Duan; Yufu Lin; Wen Zheng; Xiaopei Wang; Ningjing Lin; Meifeng Tu; Yan Xie; Chen Zhang; Weiping Liu; Lijuan Deng; Shunyu Gao; Lingyan Ping; Xuejuan Wang; Nina Zhou; Junqing Zhang; Yulong Wang; Songfeng Lin; Mierzhati Mamuti; Xueyun Yu; Lizhu Fang; Shuai Wang; Haifeng Song; Guan Wang; Lindsey Jones; Jun Zhu; Si-Yi Chen
Journal: Nat Med Date: 2019-04-22 Impact factor: 53.440

Review 5. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges.

Authors: Zijun Zhao; Yu Chen; Ngiambudulu M Francisco; Yuanqing Zhang; Minhao Wu
Journal: Acta Pharm Sin B Date: 2018-04-05 Impact factor: 11.413

5 in total

3 in total

IL-24 armored CAR19-T cells show enhanced antitumor activity and persistence.

Review 1. Targeted Nanoparticle Drug Delivery System for the Enhancement of Cancer Immunotherapy.

Review 2. Advances in targeted therapy for malignant lymphoma.

3. Low expression of Mda-7/IL-24 and high expression of C-myb in tumour tissues are predictors of poor prognosis for Burkitt lymphoma patients.

4. A safe and potent anti-CD19 CAR T cell therapy.

Review 5. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges.

Review 1. Beyond direct killing-novel cellular immunotherapeutic strategies to reshape the tumor microenvironment.

Review 2. Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies.

Review 3. How Can We Engineer CAR T Cells to Overcome Resistance?